Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study We conducted a multicenter, open-label, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results